Biosynthetic Technologies Overview
- Founded
-
2004

- Status
-
Acquired/Merged
- Employees
-
15

- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$7.5M
- Investors
-
3
Biosynthetic Technologies General Information
Description
Developer of biobased synthetic compounds designed to manufacture bio-synthetic lubricant products. The company uses a patented technology that converts fatty acids found in plant and animal oils into synthetic lubricant base oils, enabling businesses to use them for making lubricant, chemical, and cosmetics products, often outperforming their petroleum counterparts in similar applications.
Contact Information
Website
www.biosynthetic.com
Formerly Known As
LubriGreen Biosynthetics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Specialty Chemicals
Other Industries
Industrial Chemicals
Other Commercial Products
Primary Office
- 6320 Intech Boulevard
- Indianapolis, IN 46278
- United States
+1 (317) 000-0000
Biosynthetic Technologies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Later Stage VC (Series A1) | 02-Feb-2022 | $7.5M | 0000 | Completed | Generating Revenue | |
9. Later Stage VC (Series A) | 23-Mar-2019 | 00.00 | 00.00 | Completed | Generating Revenue | |
8. Secondary Transaction - Private | 05-Jun-2019 | Completed | Generating Revenue | |||
7. Merger/Acquisition | 23-Mar-2018 | 000 | 00000 | 000 | Completed | Generating Revenue |
6. Later Stage VC | 07-Feb-2017 | 000.00 | 00000 | Completed | Generating Revenue | |
5. Later Stage VC (Series D) | 01-Feb-2016 | Cancelled | Generating Revenue | |||
4. Debt - General | 01-Feb-2016 | 00000 | 00000 | Completed | Generating Revenue | |
3. Later Stage VC | 02-Oct-2014 | 0000 | 000.00 | Completed | Generating Revenue | |
2. Later Stage VC | 07-Aug-2013 | $23.7M | $30.7M | Completed | Generating Revenue | |
1. Later Stage VC | 11-May-2012 | $7M | $7M | Completed | Generating Revenue |
Biosynthetic Technologies Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biobased synthetic compounds designed to manufacture bio-synthetic lubricant products. The company uses a p
Specialty Chemicals
Indianapolis, IN
15
As of 2022
0000
00000000000
0000
Biosynthetic Technologies Competitors (7)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Anellotech | Venture Capital-Backed | Pearl River, NY | 00 | 000.00 | 0000000000 0 | 000.00 |
000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 00000000000 | 000.00 |
000 00000000000 | Private Equity-Backed | La Porte, TX | 00 | 000000000000 | ||
000000 0000000000 | Venture Capital-Backed | Ann Arbor, MI | 00 | 00.00 | 0000000000 0 | 00.00 |
00000000000000 | Venture Capital-Backed | Paris, France | 00 | 000.00 | 00000000000 | 000.00 |
Biosynthetic Technologies Patents
Biosynthetic Technologies Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170152209-A1 | Ultra high-viscosity estolide base oils and method of making the same | Abandoned | 30-Nov-2015 | 0000000000 | 0 |
EP-3383983-A1 | Ultra high-viscosity estolide base oils and method of making the same | Withdrawn | 30-Nov-2015 | 0000000000 | |
AU-2016364959-A1 | Ultra high-viscosity estolide base oils and method of making the same | Abandoned | 30-Nov-2015 | 0000000000 | |
US-20160280631-A1 | Ester compounds including triesters having terminal vicinal acyl groups | Abandoned | 25-Mar-2015 | 0000000000 | |
US-20160244397-A1 | Processes for preparing estolide base oils and biobased compounds that include ethyleneolysis | Abandoned | 20-Feb-2015 | C07C67/465 | 0 |
Biosynthetic Technologies Executive Team (12)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Mark Miller | Chief Executive Officer and Board Member | ||
Jakob Bredsguard | President | ||
Jeremy Forest JD | Chief IP Counsel | ||
Matthew Kriech Ph.D | Chief Operating Officer |
Biosynthetic Technologies Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
John Glushik | HG Ventures | Board Member | 000 0000 |
Joseph Maslowski | Self | Board Member | 000 0000 |
Mark Miller | Biosynthetic Technologies | Chief Executive Officer and Board Member | 000 0000 |
Biosynthetic Technologies Signals
Biosynthetic Technologies Former Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BP Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Calumet Specialty Products Partners | Corporation | Majority | 000 0000 | 000000 0 | |
Evonik Venture Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Sime Darby | Corporation | Minority | 000 0000 | 000000 0 |
Biosynthetic Technologies Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 | 10-Jan-2022 | 0000000000 | Distributors/Wholesale | 0000 0000 |
Biosynthetic Technologies Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
0000000 | Distributors/Wholesale | Macedonia, OH | 0000 |